Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15985674 | 0.75 | CYP11B1 (0.36) | RAB9AMEN1KMT2A | |
| SCHEMBL6058540 | 0.72 | — | — | |
| SCHEMBL24495510 | 0.70 | SLC6A2 (0.44) | RAB9AMEN1KMT2A | |
| SCHEMBL21140944 | 0.70 | HTR2A (0.46) | RAB9AMEN1KMT2A | |
| SCHEMBL20083542 | 0.70 | CYP11B1 (0.37) | MEN1KMT2A | |
| SCHEMBL3048910 | 0.69 | MEN1 (0.40) | RAB9AMEN1KMT2A | |
| SCHEMBL31681610 | 0.68 | CYP11B1 (0.38) | RAB9AMEN1KMT2A | |
| SCHEMBL16623130 | 0.68 | CYP11B1 (0.38) | RAB9AMEN1KMT2A | |
| SCHEMBL335593 | 0.68 | CHRNB2 (0.38) | RAB9A | |
| SCHEMBL6058835 | 0.68 | TSHR (0.40) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | UCB Biopharma SRL (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4267555-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-116507332-A | Octahydroisoquinolinyl derivatives | UCB生物制药有限责任公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022117678-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | OPRD1, OPRK1, OPRL1 | TRPA1 1228/4885RAB9A 1870/4885MEN1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.